Profile data is unavailable for this security.
About the company
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.
- Revenue in CAD (TTM)0.00
- Net income in CAD-39.52m
- Incorporated2012
- Employees29.00
- LocationEupraxia Pharmaceuticals Inc201-2067 Cadboro Bay Rd.VICTORIA V8R 5G4CanadaCAN
- Phone+1 (250) 590-3968
- Fax+1 (250) 590-2588
- Websitehttps://eupraxiapharma.com/home/default.aspx
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MustGrow Biologics Corp | 4.71m | -423.96k | 91.37m | 0.00 | -- | 25.36 | -- | 19.39 | -0.0078 | -0.0078 | 0.0927 | 0.0726 | 0.9337 | -- | 32.60 | -- | -8.40 | -50.41 | -11.41 | -59.28 | -- | -- | -9.00 | -298.73 | 4.84 | -- | 0.1215 | -- | 72,619.13 | 372.54 | 87.84 | -- | -- | -- |
| Satellos Bioscience Inc | 0.00 | -28.53m | 91.84m | 12.00 | -- | 4.46 | -- | -- | -0.2528 | -0.2528 | 0.00 | 0.1816 | 0.00 | -- | -- | 0.00 | -78.28 | -107.22 | -85.23 | -136.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.33 | -- | 459.46 | -- |
| Oncolytics Biotech Inc | 0.00 | -27.64m | 105.54m | 29.00 | -- | 11.66 | -- | -- | -0.3644 | -0.3644 | 0.00 | 0.1175 | 0.00 | -- | -- | -- | -78.58 | -81.99 | -104.96 | -97.25 | -- | -- | -- | -- | -- | -- | 0.1051 | -- | -- | -- | -11.75 | -- | -40.52 | -- |
| Medicenna Therapeutics Corp | 0.00 | -26.68m | 113.88m | 16.00 | -- | 5.72 | -- | -- | -0.3747 | -0.3747 | 0.00 | 0.2603 | 0.00 | -- | -- | 0.00 | -87.95 | -54.93 | -98.62 | -60.91 | -- | -- | -- | -- | -- | -2.20 | 0.0087 | -- | -- | -- | -153.44 | -- | -- | -- |
| Zentek Ltd | 39.36k | -10.74m | 166.50m | 25.00 | -- | 8.96 | -- | 4,230.28 | -0.1062 | -0.1062 | 0.0004 | 0.1785 | 0.0016 | 0.2262 | 0.1059 | 1,574.40 | -44.08 | -47.65 | -48.37 | -51.12 | -1,038.69 | -- | -27,288.92 | -13,980.33 | 1.63 | -140.86 | 0.0474 | -- | -59.07 | -- | 18.80 | -- | -19.38 | -- |
| Eupraxia Pharmaceuticals Inc | 0.00 | -39.52m | 168.49m | 29.00 | -- | 12.67 | -- | -- | -1.38 | -1.38 | 0.00 | 0.3734 | 0.00 | -- | -- | 0.00 | -162.00 | -127.84 | -261.49 | -935.99 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -52.63 | -- | -7.69 | -- |
| Cardiol Therapeutics Inc | 0.00 | -36.14m | 177.38m | 17.00 | -- | 14.94 | -- | -- | -0.5318 | -0.5318 | 0.00 | 0.1486 | 0.00 | -- | -- | -- | -119.31 | -58.97 | -158.53 | -68.62 | -- | -- | -- | -158,738.10 | -- | -- | 0.0157 | -- | -- | -- | 9.06 | -- | 36.06 | -- |
| NervGen Pharma Corp | 0.00 | -24.01m | 177.88m | 10.00 | -- | 19.35 | -- | -- | -0.37 | -0.37 | 0.00 | 0.1308 | 0.00 | -- | -- | -- | -123.68 | -121.15 | -332.31 | -180.20 | -- | -- | -- | -- | -- | -22.89 | 0.0139 | -- | -- | -- | -8.01 | -- | 2.20 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Manchester Management Co. LLCas of 01 May 2024 | 2.78m | 7.82% |
| Scotia Capital, Inc. (Broker)as of 30 Sep 2024 | 1.40m | 3.92% |
| RBC Dominion Securities, Inc. (Investment Management)as of 30 Sep 2024 | 146.29k | 0.41% |
| RBC Private Counsel (USA), Inc.as of 30 Sep 2024 | 125.00k | 0.35% |
| Faircourt Asset Management, Inc.as of 30 Jun 2024 | 65.90k | 0.19% |
| BMO Asset Management, Inc.as of 30 Sep 2024 | 49.25k | 0.14% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2024 | 34.50k | 0.10% |
| UBS Financial Services, Inc.as of 30 Sep 2024 | 33.00k | 0.09% |
| 180 Wealth Advisors LLCas of 30 Sep 2024 | 13.00k | 0.04% |
| TD Waterhouse Canada, Inc.as of 30 Sep 2024 | 1.50k | 0.00% |
